

BONE MARROW TRANSPLANT SUPPORT FOUNDATION
BONE MARROW TRANSPLANT SUPPORT FOUNDATION
C/O SHRI NEERAD J TRIVEDI FL-502 OLIVE COURT PARMAR PARK PH-I SN.77/48 WANAWADI,PUNE

BALANCE SHEET AS AT MARCH 31, 2023

	Particulars	Note No.	Amount As on 31.03.2023	Amount As on 31.03.2022
I.	EQUITY AND LIABILITIES			
1	Shareholders' funds			
	(a) Share capital	2	10,00,000	10,00,000
	(b) Reserves and surplus	3	(5,55,043)	(4,42,909)
2	Non-current liabilities			
	(a) Long-term borrowings	4		25,000
3	Current liabilities			
	(b) Other current liabilities			
	(c) Short-term provisions			
	(d) Sundry Creditors			62,471
	TOTAL		4,44,957	6,44,562
II.	ASSETS			
1	Non-current assets			
	(a) Fixed assets			
	(i) Tangible assets	5	40,915	37,631
	(ii) Intangible assets			
2	Current assets			
	(a) Cash and cash equivalents	6	4,04,042	6,18,228
	(b) Others			
	(c) Sundry Debtors			
	TOTAL		4,44,957	6,55,859
				-

Significant Accounting Policies

The accompanying notes are an integral part of the Financial Statements

As per our report on even date,
For DESHPANDE & MENDES
Firm Registration No.138147W
Chartered Accountants.

For and on behalf of the Board of Directors

UDIN NO- 23150716BGZKRE5166


Erwin Mendes
Partner
Membership No:150716
Place : Pune
Date : 07/08/2023



**NEERAD
TRIVEDI**

Director
Place : Pune
Date : 07/08/2023

**SHEETAL
VAIDYA**

Director
Place : Pune
Date : 07/08/2023

BONE MARROW TRANSPLANT SUPPORT FOUNDATION
C/O SHRI NEERAD J TRIVEDI FL-502 OLIVE COURT PARMAR PARK PH-I SN.77/48 WANAWADI,PUNE

PROFIT LOSS FOR THE YEAR ENDED 31.03.2023

	Particulars	Note No.	For the Year Ended 31.03.2023 Amount`	For the Year Ended 31.03.2022 Amount`
I.	Revenue from operations	7	5,20,293	-
II.	Total Revenue (I)		5,20,293	-
III	Expenses:			
	(a) Administrative and Selling Expenses	8	5,77,040	2,36,517
	(b) Depreciation and amortization expense		55,387	23,768
IV	Total expenses		6,32,427	2,60,285
V	Profit before exceptional and extraordinary items and tax (III-IV)		(1,12,134)	(2,60,285)
VI	Exceptional / Extraordinary items			
VII	Profit before tax (V- VI)		(1,12,134)	(2,60,285)
VIII	Tax expense:			
	(1) Current tax			
	(2) Deferred tax			
IX	Profit (Loss) for the period from continuing operations (VII-VIII)		(1,12,134)	(2,60,285)
X	Profit (Loss) for the period (X)		(1,12,134)	(2,60,285)
XI	Earnings per equity share:			
	(1) Basic	9	(1.12)	(2.60)
	(2) Diluted		(1.12)	(2.60)

Significant Accounting Policies

The accompanying notes are an integral part of the Financial Statements

1

As per our report on even date,
For DESHPANDE & MENDES
Firm Registration No.138147W
Chartered Accountants.


Erwin Mendes
Partner
Membership No:150716
Place : Pune
Date : 07/08/2023



For and on behalf of the Board of Directors

UDIN NO- 23150716BGZKRE5166

NEERAD TRIVEDI
Director
Place : Pune
Date : 07/08/2023

SHEETAL VAIDYA
Director
Place : Pune
Date : 07/08/2023

BONE MARROW TRANSPLANT SUPPORT FOUNDATION

Notes forming part of the Financial Statements for the period ended 31.03.2023

Note No 2 : Share Capital

Sr. No.	Particulars	As at 31 March 2023		As at 31 March 2022	
		Number	Amount	Number	Amount
1	Authorised, Issued, Subscribed and Paid-up Share Capital	1,00,000	10,00,000	1,00,000	10,00,000
	Authorised				
	Equity Shares of ` /- each	1,00,000	10,00,000	1,00,000	10,00,000
	Issued, Subscribed & Paid-up Equity Share Capital				
	Equity Shares of ` 10/- each fully paid	1,00,000	10,00,000	1,00,000	10,00,000
	Total	1,00,000	10,00,000	1,00,000	10,00,000
3	Reconciliation of the number of Share Outstanding				
	Shares outstanding at the beginning of the year	1,00,000	10,00,000		
	Shares Issued during the year			1,00,000	10,00,000
	Shares bought back during the year				
	Shares outstanding at the end of the year	1,00,000	10,00,000	1,00,000	10,00,000
3	Shareholders' holding more than 5% equity share of the company				
		As at 31 March 2023		As at 31 March 2022	
	Name of Shareholder	No. of Shares held	% of Holding	No. of Shares held	% of Holding
1	Neerad Trivedi	50,000	50%	50,000	50.00%
2	Sheetal Vaidya	50,000	50%	50,000	50.00%



BONE MARROW TRANSPLANT SUPPORT FOUNDATION
Notes forming part of the Financial Statements for the period ended 31.03.2023

Note No 3 : Reserves and surplus

Sr. No.	Particulars	As at 31 March 2023	As at 31 March 2022
		Amount	Amount
1	General Reserve		
	Profit & Loss Account balance		
	Opening balance	(4,42,909)	(1,82,624)
	(+) Net Profit/(Net Loss) For the current year	(1,12,134)	(2,60,285)
	Closing Balance	(5,55,043)	(4,42,909)

Note No 6 : Cash and cash equivalents

Sr. No.	Particulars	As at 31 March 2023	As at 31 March 2022
		Amount	Amount
1	Balances with banks HDFC-2646	3,93,167	6,18,228
2	Cash In Hand	10,875	-
	Total	4,04,042	6,18,228

Note No 7 : Revenue from operations

Sr. No.	Particulars	As at 31 March 2023	As at 31 March 2022
		Amount	Amount
1	Receipts	4,57,822	-
2	Written Off	62,471	-
	Total	5,20,293	-



BONE MARROW TRANSPLANT SUPPORT FOUNDATION

Notes forming part of the Financial Statements for the period ended 31.03.2023

Note No 8 : Administrative and Selling Expenses

Sr. No.	Particulars	As at 31 March 2023	As at 31 March 2022
		Amount	Amount
1	Handbook for Patients	23,000	
2	Material Purchase	29,500	
3	Telephone & Internet Expenses	10,466	
4	Yoga Charges	40,000	
5	Director Remuneration	2,75,000	2,30,634
6	Website & Digital Marketing Expense	62,958	-
7	Bank Charges	23	-
8	Consultant Exp	25,000	-
9	Audit Fees	35,000	5,883
10	Advertisement Expenses	28,944	
11	IT Form Filing Fees	10,000	
12	Miscl Expenses	6,253	
13	Petrol Expenses	16,371	
14	Travelling Expenses	14,525	
	Total	5,77,040	2,36,517

Note No. 9: Earnings Per Share

Sr. No.	Particulars	As at 31 March 2023	As at 31 March 2022
	Nominal Value of Equity Shares	10	10
	Profit attributable to Equity Shareholders	(1,12,134)	(2,60,285)
	Weighted average number of shares outstanding during the period	1,00,000	1,00,000
	Basic earnings per share	(1.12)	(2.60)
	Dilutive effect on weighted average number of Equity Shares outstanding during the year	(1,12,134)	(2,60,285)
	Weighted average number of diluted shares outstanding during the period	1,00,000	1,00,000
	Diluted earnings per share	(1.12)	(2.60)

Note No. 4: Long term borrowing

Sr. No.	Particulars	As at 31 March 2023	As at 31 March 2022
		Amount	Amount
1	Directors Loan		25,000
	Total	-	25,000



BONE MARROW TRANSPLANT SUPPORT FOUNDATION
Notes forming part of the Financial Statements for the period ended 31.03.2023

Note No 5 : Fixed assets

	Fixed Assets	WDV Rate	Balance as at 01 April 2022	Gross Carrying Value		Depreciation charge for the year	Net Carrying Balance as at 31 March 2023
				Addition	Less than 180 days		
a	Tangible Assets						
	Dell Laptop	63.16	13,863			8,756	5,107
	Furniture	25.89%		14,589		3,777	10,812
	Software	63.16%		67,850		42,854	24,996
	Total					55,387	40,915
b	Intangible assets						
	Total						
	Grand Total					55,387	40,915

For and on behalf of the Board of Directors

UDIN NO- 23150716BGZKRE5166



(Signature)

Erwin Mendes
Partner


Membership No:150716
Place : Pune
Date : 07/08/2023

NEERAD TRIVEDI

Director
Place : Pune
Date : 07/08/2023

SHEETAL VAIDYA

Director
Place : Pune
Date : 07/08/2023



Deshpande & Mendes
CHARTERED ACCOUNTANTS

'DHANANJAY ETERNIA', CTS2129,
Flat No-102,1st Floor, Opp.Joshi's Academy,
Vijay Nagar Colony,Tilak Road,Sadashiv Peth

Email: support@deshpandemendes.com,

Tel: 24459520,24332005

INDEPENDENT AUDITORS' REPORT

TO,

The Members of

BONE MARROW TRANSPLANT SUPPORT FOUNDATION

Report on the Financial Statements

We have audited the accompanying financial statements of **BONE MARROW TRANSPLANT SUPPORT FOUNDATION** (the "Company"), which comprise the Balance sheet as at 31st March ,2023 the Statement of Profit and Loss and the Cash Flow Statement for the year then ended, and a summary of the significant accounting policies and other explanatory Information.

Management's Responsibility for the Financial Statements

The Company's Management is responsible for the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the Accounting Standards notified under the Companies Act, 1956 ("the Act") (which continue to be applicable in respect of Section 133 of the Companies Act, 2013 in terms of General Circular 15/2013 dated 13th September, 2013 of the Ministry of Corporate Affairs) and in accordance with the accounting principles generally accepted in India. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.



Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2003 (the "Order") issued by the Central Government in terms of Section 227(4A) of the Act, is not applicable to the company.
2. As required by Section 227(3) of the Act, we report that:
 - a. We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c. The Balance Sheet, the Statement of Profit and Loss dealt with by this Report are in agreement with the books of account.
 - d. In our opinion, the Balance Sheet, the Statement of Profit and Loss comply with the Accounting Standards notified under the Act (which continue to be applicable in respect of Section 133 of the Companies Act, 2013 in terms of General Circular 15/2013 dated 13th September, 2013 of the Ministry of Corporate Affairs).
 - e. On the basis of the written representations received from the directors taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2023 from being appointed as a director in terms of Section 274(1)(g) of the Act.

For DESHPANDE & MENDES

Chartered Accountants

(Firm's Registration Number: 138147W)

Erwin Mendes

Partner

(Membership No. 150716)

Date – 07/08/2023

Place – Pune

UDIN: 23150716BGZKRE5166

